Chardan Capital Estimates Krystal Biotech FY2026 Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) – Stock analysts at Chardan Capital issued their FY2026 earnings per share estimates for Krystal Biotech in a research report issued on Thursday, February 20th. Chardan Capital analyst Y. Livshits anticipates that the company will post earnings per share of $9.95 for the year. Chardan Capital has a “Buy” rating and a $218.00 price target on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share.

Several other brokerages also recently weighed in on KRYS. Citigroup increased their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday, February 20th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research report on Wednesday, February 19th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $210.00.

Krystal Biotech Stock Down 3.1 %

Shares of KRYS opened at $181.10 on Monday. The business has a fifty day moving average of $158.24 and a 200 day moving average of $175.31. The company has a market cap of $5.22 billion, a PE ratio of 60.57 and a beta of 0.84. Krystal Biotech has a 52-week low of $125.85 and a 52-week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.29 by $0.23. The business had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company’s revenue for the quarter was up 116.4% on a year-over-year basis. During the same period last year, the company earned $0.30 EPS.

Insiders Place Their Bets

In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the transaction, the insider now directly owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 14.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Krystal Biotech

A number of hedge funds have recently made changes to their positions in the stock. Wilmington Savings Fund Society FSB purchased a new stake in Krystal Biotech during the 3rd quarter worth about $40,000. GF Fund Management CO. LTD. purchased a new position in Krystal Biotech during the 4th quarter worth $95,000. Huntington National Bank increased its position in Krystal Biotech by 97.6% in the 3rd quarter. Huntington National Bank now owns 573 shares of the company’s stock valued at $104,000 after acquiring an additional 283 shares during the period. Blue Trust Inc. raised its stake in shares of Krystal Biotech by 242.4% during the third quarter. Blue Trust Inc. now owns 582 shares of the company’s stock worth $107,000 after purchasing an additional 412 shares during the last quarter. Finally, Covestor Ltd lifted its stake in shares of Krystal Biotech by 972.7% in the 4th quarter. Covestor Ltd now owns 708 shares of the company’s stock worth $111,000 after acquiring an additional 642 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).